These findings suggest that combined Hes and ADR treatment exerts a stronger antiproliferative effect than single-agent exposure, implying potential therapeutic benefit through enhanced suppression of ovarian cancer cell growth. Here, RRBP1 is linked to ovarian carcinoma.